invasive fungal infections and leishmaniasis · reviewed 2026-08-01
Amphotericin B and Streptomyces: one natural antifungal, different pharmaceutical forms
Streptomyces nodosus makes amphotericin B itself. A liposomal injection carries that same molecule in a designed lipid structure, and the label warns that amphotericin products differ in pharmacology, exposure, and dosing.
Defined medicine
liposomal amphotericin B injection
amphotericin B liposome for injection · AmB
Where it came from
Amphotericin B is a macrocyclic polyene antifungal antibiotic produced by Streptomyces nodosus. The active molecule remains the microbial natural product inside the cited liposomal formulation. dailymed-amphotericin-liposomal amphotericin-history-2020
What it is trying to achieve
The cited liposomal injection is labelled for selected serious fungal-infection settings, cryptococcal meningitis, certain infections when conventional amphotericin is unsuitable, and visceral leishmaniasis. dailymed-amphotericin-liposomal
How it acts
Amphotericin B binds ergosterol in susceptible fungal membranes and forms channels that leak ions, disrupting membrane function and causing cell death. The same binding can contribute to toxicity in human tissues. dailymed-amphotericin-liposomal
Why people developed this form
Screening a soil-derived Streptomyces fermentation revealed amphotericin B as a potent antifungal natural product. Liposomal formulation then pursued delivery that changes distribution and reduces some toxicity relative to older forms. amphotericin-history-2020 dailymed-amphotericin-liposomal
Present form and manufacture
In the cited intravenous product, amphotericin B is intercalated within a single-bilayer liposomal membrane and is integral to that structure. The label states that it is not interchangeable on an equal-amount basis with other amphotericin B products because their pharmacodynamics, pharmacokinetics, and dosing differ. dailymed-amphotericin-liposomal
Bioavailability
Intravenous liposomes alter amphotericin B distribution and exposure, and the label reports nonlinear pharmacokinetics and tissue persistence. Values from this formulation cannot be transferred to conventional or other lipid products. dailymed-amphotericin-liposomal
Its own risks
Important risks include infusion reactions, anaphylaxis, nephrotoxicity, low potassium and magnesium, anemia, liver abnormalities, and interactions with other kidney-toxic or electrolyte-altering medicines. dailymed-amphotericin-liposomal
What nature offers
No link below is assumed to be equivalent. Each names the organism or tradition, exact preparation, measured exposure, human evidence, and replacement boundary separately.
Nature link · Same molecule occurs in nature
amphotericin B from Streptomyces fermentation
Streptomyces nodosus
fermentation-derived amphotericin B · polyene natural product
- Exact material
- Purified amphotericin B produced by Streptomyces nodosus fermentation, kept distinct from the organism, Venezuelan soil sample, crude broth, conventional deoxycholate product, and liposomal injection. dailymed-amphotericin-liposomal amphotericin-history-2020
- Relationship
- Same molecule occurs in nature. Chemical identity may match, but purity, amount, formulation, route, companion compounds, and evidence can still differ.
Lineage
Streptomyces nodosus produces the final amphotericin B molecule itself. Purification retains that natural product, while liposomal formulation changes its delivery rather than changing the active molecule's identity. dailymed-amphotericin-liposomal amphotericin-history-2020
Human evidence
Source, not an intervention Evidence product match: not applicable
The organism, soil, fermentation broth, and unformulated purified amphotericin B are discovery or manufacturing materials, not the sterile liposomal intervention tested for serious infection. Their clinical efficacy is not established by the product label. dailymed-amphotericin-liposomal amphotericin-history-2020
Bioavailability and preparation
The label's exposure and tissue-distribution findings belong to intravenous liposomal amphotericin B. They do not describe an organism, soil, broth, purified powder alone, or another amphotericin formulation. dailymed-amphotericin-liposomal
Safety
Microbial origin does not remove amphotericin B's kidney, electrolyte, infusion, blood, liver, or interaction risks. Crude biological material has no sterility, potency, formulation, or safety support in the cited record. dailymed-amphotericin-liposomal
Can it replace the medicine?
Streptomyces, soil, fermentation broth, and unformulated amphotericin are not clinical substitutes for liposomal injection; other amphotericin products are not automatically equivalent either. dailymed-amphotericin-liposomal
Ecology
The cited history traces the producing culture to a soil sample from the Orinoco basin in Venezuela. That place belongs in the discovery provenance without turning local soil into a therapeutic material. amphotericin-history-2020
The honest comparison
The active molecule is naturally produced and unchanged, yet intervention identity still depends on purification, sterility, liposome structure, intravenous delivery, infection context, and formulation-specific pharmacology. dailymed-amphotericin-liposomal amphotericin-history-2020
Nature made amphotericin B; formulation engineering made materially different medicines from it. The label's non-interchangeability warning is the practical answer to any claim that the natural molecule alone defines the treatment. dailymed-amphotericin-liposomal
Sources for this card
- Liposomal amphotericin B injection prescribing information DailyMed · regulatory label · read 2026-08-01
- Amphotericin B and other polyenes: discovery, clinical use, mode of action and drug resistance Journal of Fungi · scholarly history · read 2026-08-01
Same card as data: /api/remedies/amphotericin-b-streptomyces.json. Found a source or claim problem? Open a correction.